Neuphoria Therapeutics Inc (NEUP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,042 | -9,907 | -370 | 8,514 | -2,748 |
| Depreciation Amortization | 332 | 166 | 663 | 497 | 332 |
| Accounts receivable | -1,098 | 10 | 115 | 102 | 91 |
| Accounts payable and accrued liabilities | -634 | 216 | -918 | -1,498 | -713 |
| Other Working Capital | -2,089 | 1,384 | -497 | -2,169 | -1,527 |
| Other Operating Activity | 1,301 | 4,336 | 1,084 | -1,784 | -3,226 |
| Operating Cash Flow | $-10,231 | $-3,795 | $77 | $3,662 | $-7,791 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 17,916 | 3,254 | 1,528 | 824 | N/A |
| Other Financing Activity | 0 | 0 | 0 | 0 | -339 |
| Financing Cash Flow | $17,916 | $3,254 | $1,528 | $824 | $-339 |
| Exchange Rate Effect | 276 | -20 | -4 | -53 | -138 |
| Beginning Cash Position | 14,289 | 14,289 | 12,687 | 12,687 | 12,687 |
| End Cash Position | 22,250 | 13,728 | 14,289 | 17,120 | 4,419 |
| Net Cash Flow | $7,961 | $-561 | $1,602 | $4,433 | $-8,268 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,231 | -3,795 | 77 | 3,662 | -7,791 |
| Free Cash Flow | -10,231 | -3,795 | 77 | 3,662 | -7,791 |